Ramesh K. Ramanathan, MD

Dr. Ramesh K. Ramanathan is an Origin partner, a medical oncologist, and the Director of Clinical Research at Ironwood Physicians in Scottsdale, AZ. He leverages his extensive experience in academia and industry to accelerate global access to innovative new agents for patients in need.

Additionally, Ramesh is at the forefront of a platform transforming the development of highly specialized next-generation early phase investigators and support staff. Success in this area has the potential to unleash the full impact of remarkable medical breakthroughs requiring rare know-how and game-changing drug development thinking. This initiative represents a critical challenge and opportunity for the clinical and research communities to advance healthcare for all.

Dr. Ramanathan held the position of Executive Director of Global Scientific Affairs at Merck Research Labs and Vice President at Zielbio.

Dr. Ramanathan served on the faculty of Mayo Clinic and held appointments as Professor of Medicine at the Mayo Medical school with a joint appointment at the Translational Genomics Research Institute (TGEN) Prior to joining Mayo Clinic, he served as the medical director of the Virginia G. Piper Cancer Ctr- Clinical Trials Program and the University of Pittsburgh Cancer Institute.

Dr. Ramanathan is a recognized expert for GI cancers and has research interests in new drug development. In the last 25 years, Dr. Ramanathan has been involved in the development of several new drugs (PARP, PI3K, hedgehog inhibitors, liposomal formulations etc), participated in numerous first in human agent studies and had a pivotal role in the development and approval of oxaliplatin for colon cancer and nab-paclitaxel for pancreatic cancer.  He has published more than 200 papers in peer reviewed journals, as well as numerous book chapters. Dr Ramanathan has served on national professional committees and been an invited speaker at national and international meetings. Dr. Ramanathan is an Editorial Board member for Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Gastrointestinal Cancer Research and is an ad hoc reviewer for several high impact journals.